CheckMate 214 patient-reported outcomes: listening to our patients. - Suppr | 超能文献

CheckMate 214 patient-reported outcomes: listening to our patients.

作者信息

Massari Francesco, Di Nunno Vincenzo

机构信息

Division of Oncology, Policlinico Sant'Orsola-Malpighi Hospital, Bologna 40138, Italy.

Division of Oncology, Policlinico Sant'Orsola-Malpighi Hospital, Bologna 40138, Italy.

出版信息

Lancet Oncol. 2019 Feb;20(2):179-180. doi: 10.1016/S1470-2045(18)30790-3. Epub 2019 Jan 15.

DOI:10.1016/S1470-2045(18)30790-3

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

CheckMate 214 patient-reported outcomes: listening to our patients.

Lancet Oncol. 2019 Feb;20(2):179-180. doi: 10.1016/S1470-2045(18)30790-3. Epub 2019 Jan 15.

2

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.纳武利尤单抗联合伊匹木单抗与舒尼替尼治疗晚期肾细胞癌的比较

N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.

3

CheckMate 214 - a winning combination?CheckMate 214——一个成功的组合？

Nat Rev Clin Oncol. 2018 Jun;15(6):343. doi: 10.1038/s41571-018-0020-4.

4

Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.纳武利尤单抗联合伊匹单抗治疗失败后的转移性肾细胞癌二线靶向治疗。

Eur J Cancer. 2019 Feb;108:33-40. doi: 10.1016/j.ejca.2018.11.031. Epub 2019 Jan 5.

5

[Risk Classification and Nivolumab plus Ipilimumab Combination Therapy for Treatment of Renal Cell Carcinoma].

Gan To Kagaku Ryoho. 2019 Sep;46(9):1397-1404.

6

Re: Nivolumab plus Ipilimumab Versus Sunitinib in Advanced Renal-cell Carcinoma.回复：纳武利尤单抗联合伊匹木单抗对比舒尼替尼治疗晚期肾细胞癌

Eur Urol. 2018 Nov;74(5):679-680. doi: 10.1016/j.eururo.2018.07.019. Epub 2018 Aug 10.

7

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma.纳武利尤单抗联合伊匹单抗作为晚期肾细胞癌一线治疗的成本效果分析。

J Immunother Cancer. 2018 Nov 20;6(1):124. doi: 10.1186/s40425-018-0440-9.

8

[Nivolumab combined with ipilimumab versus sunitinib monotherapy-SUNNIFORECAST AN 41/16 of the AUO : A phase 2, randomized, open-label study in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell renal cell carcinoma].纳武利尤单抗联合伊匹木单抗对比舒尼替尼单药治疗——AUO的SUNNIFORECAST AN 41/16：一项针对既往未接受治疗的晚期（不可切除或转移性）非透明细胞肾细胞癌患者的2期随机开放标签研究

Urologe A. 2017 Jun;56(6):802-803. doi: 10.1007/s00120-017-0397-1.

9

Kidney cancer: Antibody pincer movement challenges sunitinib as standard therapy.肾癌：抗体夹击疗法对舒尼替尼作为标准疗法构成挑战。

Nat Rev Urol. 2018 May;15(5):261. doi: 10.1038/nrurol.2018.47. Epub 2018 Apr 10.

10

Conditional Survival in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab.纳武利尤单抗治疗晚期肾细胞癌患者的条件生存。

Med Sci Monit. 2019 Aug 30;25:6518-6522. doi: 10.12659/MSM.916984.

引用本文的文献

1

Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor.肾细胞癌对全身治疗药物的耐药性：预测并克服肿瘤采用的基因组策略

Cancers (Basel). 2019 Jun 14;11(6):830. doi: 10.3390/cancers11060830.